Patient | Age (y) | HER2 status in primary tumor before imaging (IHC/FISH) | HER2 gene amplification (determined after imaging) | Primary tumor status (ER/PgR) | Clinical stage before imaging |
---|---|---|---|---|---|
1,000 μg; mean tumor size, 28 ± 11 mm | |||||
1 | 68 | 1+ (IHC) | FISH- | ER+/PgR- | IIA (T2N0M0) |
2 | 62 | 1+ (IHC) | FISH- | ER+/PgR+ | I (T1N0M0) |
3 | 66 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
4 | 48 | 0 (IHC) | FISH- | ER-/PgR- | IIA (T2N0M0) |
5 | 50 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
6 | 70 | 3+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
7 | 30 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIB (T2N1M0) |
8 | 59 | 2+ (IHC)/FISH+ | ER-/PgR- | IIA (T2N0M0) | |
9 | 45 | (IHC)3+ | FISH- | ER+/PgR- | IIB (T2N1M0) |
2,000 μg; mean tumor size, 25 ± 6 mm | |||||
10 | 50 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
11 | 57 | 1+ (IHC) | FISH- | ER+/PgR+ | I (T1N0M0) |
12 | 43 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
13 | 51 | 1+ (IHC) | FISH- | ER-/PgR- | IIA (T2N0M0) |
14 | 65 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
15 | 35 | 3+ (IHC) | FISH+ | ER+/PgR+ | I (T1N0M0) |
16 | 50 | 1+ (IHC)* | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
17 | 68 | 2+ (IHC)/FISH+ | ER+/PgR- | IIA (T2N0M0) | |
18 | 68 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
3,000 μg; mean tumor size 22 ± 7 mm | |||||
19 | 37 | 1+ (IHC) | FISH- | ER-/PgR- | IIA (T2N0M0) |
20 | 45 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
21 | 56 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
22 | 45 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
23 | 36 | 1+ (IHC) | FISH- | ER+/PgR+ | IIA (T2N0M0) |
24 | 48 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIВ (T2N1M0) |
25 | 58 | 3+ (IHC) | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
26 | 47 | 1+ (IHC)* | FISH+ | ER+/PgR+ | IIA (T2N0M0) |
27 | 61 | 3+ (IHC) | FISH+ | ER+/PgR- | IV (T4N3M1) |
28 | 49 | 3+ (IHC) | FISH+ | ER+/PgR+ | I (T1N0M0) |
* Postimaging FISH evaluation demonstrated HER2 gene amplification.
IHC = immunohistochemistry; ER = estrogen receptor; PgR = progesterone receptor;+ = positive; - = negative.